AU2019326438A1 - B7-H7-binding agents and methods of use thereof - Google Patents

B7-H7-binding agents and methods of use thereof Download PDF

Info

Publication number
AU2019326438A1
AU2019326438A1 AU2019326438A AU2019326438A AU2019326438A1 AU 2019326438 A1 AU2019326438 A1 AU 2019326438A1 AU 2019326438 A AU2019326438 A AU 2019326438A AU 2019326438 A AU2019326438 A AU 2019326438A AU 2019326438 A1 AU2019326438 A1 AU 2019326438A1
Authority
AU
Australia
Prior art keywords
seq
variable region
chain variable
binding agent
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019326438A
Other languages
English (en)
Inventor
Suzanne Christine CRAWLEY
Jer-Yuan HSU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NGM Biopharmaceuticals Inc
Original Assignee
NGM Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NGM Biopharmaceuticals Inc filed Critical NGM Biopharmaceuticals Inc
Publication of AU2019326438A1 publication Critical patent/AU2019326438A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019326438A 2018-08-21 2019-08-20 B7-H7-binding agents and methods of use thereof Abandoned AU2019326438A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720708P 2018-08-21 2018-08-21
US62/720,708 2018-08-21
PCT/US2019/047250 WO2020041300A1 (en) 2018-08-21 2019-08-20 B7-h7-binding agents and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2019326438A1 true AU2019326438A1 (en) 2021-03-04

Family

ID=67841214

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019326438A Abandoned AU2019326438A1 (en) 2018-08-21 2019-08-20 B7-H7-binding agents and methods of use thereof

Country Status (7)

Country Link
US (1) US20210198366A1 (https=)
EP (1) EP3850009A1 (https=)
JP (1) JP2021533796A (https=)
CN (1) CN112930357A (https=)
AU (1) AU2019326438A1 (https=)
CA (1) CA3108905A1 (https=)
WO (1) WO2020041300A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110760483B (zh) * 2019-11-08 2021-06-22 扬州大学 具牛、羊交叉反应的抗TNF-α单克隆抗体的制备及应用
WO2023138579A1 (zh) * 2022-01-21 2023-07-27 和铂医药美国股份有限公司 抗b7-h7抗体或其抗原结合片段及制备方法和应用
WO2023173393A1 (zh) * 2022-03-18 2023-09-21 北京天广实生物技术股份有限公司 结合b7-h3的抗体及其用途
WO2025040144A1 (zh) * 2023-08-23 2025-02-27 南京再明医药有限公司 B7-h7抗原结合分子及其应用
CN119841949A (zh) * 2023-10-17 2025-04-18 科辉智药(深圳)新药研究中心有限公司 一种抗人hhla2的纳米抗体及其应用
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof
WO2025175056A1 (en) * 2024-02-15 2025-08-21 Nextpoint Therapeutics, Inc. Multispecific antibodies or antigen binding fragments thereof to b7-h7 and immune effector cell antigens
CN121005781A (zh) * 2024-05-24 2025-11-25 合肥天港免疫药物有限公司 高亲和力b7h7抗体或其抗原结合片段及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2666152T3 (es) * 2009-08-13 2018-05-03 The Johns Hopkins University Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR
WO2014133728A2 (en) * 2013-03-01 2014-09-04 Albert Einstein College Of Medicine Of Yeshiva University Hhla2 as a novel inhibitor of human immune system and uses thereof
WO2015187359A1 (en) * 2014-06-04 2015-12-10 Ngm Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway

Also Published As

Publication number Publication date
JP2021533796A (ja) 2021-12-09
CA3108905A1 (en) 2020-02-27
US20210198366A1 (en) 2021-07-01
EP3850009A1 (en) 2021-07-21
WO2020041300A1 (en) 2020-02-27
CN112930357A (zh) 2021-06-08

Similar Documents

Publication Publication Date Title
US12410251B2 (en) ILT-binding agents and methods of use thereof
US12187796B2 (en) ILT3-binding agents and methods of use thereof
US20210198366A1 (en) B7-h7-binding agents and methods of use thereof
US20180346571A1 (en) Pd-l1-binding agents and uses thereof
WO2018017864A2 (en) Pvrig-binding agents and uses thereof
US12240899B2 (en) LAIR-1-binding agents and methods of use thereof
US20180222958A1 (en) Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
US20170044268A1 (en) Immunotherapy with Binding Agents
WO2016033284A1 (en) Combination therapy for treatment of cancer
WO2023235706A1 (en) Combination therapies using ilt-binding agents and pd-1 inhibitors
US20170267758A1 (en) Immunotherapy with binding agents
WO2023173091A1 (en) Osteoclast-associated ig-like receptor (oscar) and methods of use thereof
US20170247437A1 (en) Rspo1 binding agents and uses thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application